Evergy Inc. Common Stock vs Novavax Inc — how do they compare? Evergy Inc. Common Stock trades at $81.8 (market cap $18.57B), while Novavax Inc trades at $11.1 (market cap $1.82B). The key difference: Evergy Inc. Common Stock is far larger — about 10.2× Novavax Inc's market cap, and Evergy Inc. Common Stock pays a 3.45% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Evergy Inc. Common Stock for 0 Days and Novavax Inc for 59 Days on average.
| EVRG | NVAX | |
|---|---|---|
Market Cap | $18.57B | $1.82B |
Volume | 1,988,675 | 6,198,505 |
Sector | Utilities | Health |
52-Week High | $88.13 | $12.56 |
52-Week Low | $72.31 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $35.04B | $1.39B |
Dividend Yield | 3.45% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Evergy is a regulated electric utility serving customers in Kansas and Missouri. Its operations include electricity generation, transmission, and distribution through its integrated utility subsidiaries.
Read more on EVRG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →